<DOC>
	<DOCNO>NCT00261521</DOCNO>
	<brief_summary>The purpose study early hemodialysis patient ( dialysis 3 18 month ) assess effect correction versus partial correction anemia use epoetin alfa heart pump function .</brief_summary>
	<brief_title>A Study Safety Efficacy Long-term Correction Anemia With Epoetin Alfa Early Hemodialysis Patients</brief_title>
	<detailed_description>Cardiovascular disease common among patient end-stage renal disease . This study long-term , double-blind , parallel-group , multicenter study determine efficacy safety administer epoetin alfa treat anemia ( patient Group 1 ) partially treat anemia ( patient Group 2 ) order reduce risk heart failure chronic renal failure patient early dialysis improve quality life . Efficacy epoetin alfa determine compare Group 1 Group 2 heart structure ( change leave ventricle volume mass view echocardiogram ) , development heart failure , correlation change heart structure hemoglobin level , 6-minute walk test , 2 quality life measures-a quality life questionnaire fatigue questionnaire . Safety data associate elevation hemoglobin collect monitor throughout study : hemoglobin-related adverse event include thrombovascular event , seizure , hypertension . Development antibodies erythropoetin long-term treatment also assess serum sample gather course study . The hypothesis study earlier longer-term anemia intervention patient without symptomatic heart disease heart architecture distortion may conserve heart function improve quality life , intervention well tolerated patient . Patients epoetin alfa start : epoetin alfa ( 50 IU/kg ) , 3 time per week increase every 4 week either 25 IU/kg 25 % previous dose reach target hemoglobin ( Hb ) , dose maintain . Patients switch epoetin alfa start titrate maintain target Hb .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>On hemodialysis 3 18 month expect remain hemodialysis least two year life expectancy year Kidney transplant patient , whose transplant fail , hemodialysis 318 month , may eligible study , receive excessive immunosuppression ( e.g. , &lt; =10 mg steroids/day allow ) Predialysis hemoglobin 812 g/dL , inclusive , within previous month ( single reading sufficient ) Stable hemodialysis vascular access , within previous 3 month No heart disease asymptomatic heart disease without enlarged heart Heart diseases surgical intervention occur previous two year may require intervention within next year Patients medical condition likely affect response epoetin Predialysis sit diastolic blood pressure &gt; = 100 mmHg average previous month Folate , Vitamin B12 , transferrin deficiency History seizure within 1 year Transfusion within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Kidney failure , Chronic</keyword>
	<keyword>End-stage renal disease</keyword>
	<keyword>Kidney failure</keyword>
	<keyword>Anemia</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Epoetin</keyword>
	<keyword>Erythropoetin</keyword>
	<keyword>Epoetin alfa</keyword>
</DOC>